Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it has acquired Celsee, Inc., a company that offers instruments and consumables for the isolation, detection, and analysis of single cells. Terms of the acquisition were not disclosed. Bio-Rad will discuss the acquisition in more detail during its first-quarter 2020 financial results conference call.
Celsee’s Genesis System offers a practical, scalable, and efficient approach to accurately analyze single cells. Using the Genesis System, scientists can isolate, analyze, and interpret cellular behavior and collect cell-based information for improved results in applications such as single-cell cytometry, single-cell transcriptomics, single-cell multiomics, rare-cell enrichment and enumeration, and immune monitoring. The system can scale from hundreds of thousands to millions of cells for genomic and proteomic applications and can enrich or monitor circulating tumor cells to determine disease progression and therapeutic response.
"We are pleased to have Celsee join Bio-Rad," said Norman Schwartz, Bio-Rad President and CEO. "Their innovative products and technologies will extend our reach into the rapidly growing world of precision medicine and single-cell analysis, both of which offer enhanced insight into disease, diagnosis, and treatment."
Founded in 2011 and based in Ann Arbor, Michigan, Celsee’s customers include research, translational, and biopharma laboratories worldwide.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 150,000 research and healthcare industry customers through its global network of operations. The company employs more than 8,000 people worldwide and had revenues exceeding $2.3 billion in 2019. For more information, please visit bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations regarding the acquisition of Celsee, Inc. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company’s risks and uncertainties, please refer to the "Risk Factors" and "Management’s Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
Bio-Rad Laboratories, Inc.
Tina Cuccia, Corporate Communications